Spyre Therapeutics SYRE
NASDAQ SYRE
$93.19 +3.26 (+3.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Spyre Therapeutics (SYRE) Non Operating Investment Income (2023 - 2026)

Updated

Spyre Therapeutics (SYRE) recorded Non Operating Investment Income of $40 million in Q2 2026, up 300.0% from $10 million a year earlier and up 33.3% from the prior quarter.

Analysis

Spyre Therapeutics (SYRE) Non Operating Investment Income (2023 - 2026) Analysis & Trends

On a TTM basis, Spyre Therapeutics' Non Operating Investment Income came in at $70 million as of Jun 30, 2026, up 600.0% year-over-year; for FY2025, it came in at $10 million.

  • Across earlier years, Non Operating Investment Income came in at $16.45 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Spyre Therapeutics 8.21 Bn 8.21 Bn - 40.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Mar 31, 2026 30.00 Mn
Jun 30, 2025 10.00 Mn
Dec 31, 2023 1.84 Mn
Sep 30, 2023 14.61 Mn
API Access

Spyre Therapeutics Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=SYRE&period=max&api_key=YOUR_API_KEY